You are here

Article Text

Article menu
Download PDFPDF
Letters
Homocysteine, a marker of cardiovascular disease risk, is markedly elevated in patients with gout
  1. Ole Slot
  1. Correspondence to Dr Ole Slot, Department of Rheumatology, Copenhagen University Hospital Glostrup, Ndr. Ringvej, Glostrup DK-2600, Denmark; ole.slot.01{at}regionh.dk

https://doi.org/10.1136/annrheumdis-2012-202023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Homocysteine (Hcy) is an amino acid formed by demethylation of methionine. Impaired renal function, enzymatic polymorphisms, and low levels of B-group vitamins dispose to hyperhomocysteinaemia (HHcy).1 ,2 HHcy as well as hyperurecaemia induce reactive oxygen species and impair endothelial function1 ,3 and are associated with increased risk of cardiovascular disease (CVD).1–4 Hcy and urate possibly have additive effects on the endothelial function.5

    Studies in normal populations have shown positive correlations between p-Hcy and p-urate,6 ,7 but reports on the prevalence of HHcy in gout patients have shown conflicting results.8–10

    To study the prevalence of HHcy in gout—133 …

    View Full Text

    Footnotes

    • Contributors The author collected the data, conducted the study and wrote the manuscript.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.